Scientists Crack 30-Year Genetic Mystery Behind Severe Inflammatory Bowel Disease

A team from the University of Oxford, Newcastle University, and Cambridge University Hospitals NHS Foundation Trust has solved a 30-year-old genetic mystery at the heart of inflammatory bowel disease (IBD), publishing findings in the New England Journal of Medicine. The study examined more than 4,900 patients with IBD — both Crohn's disease and ulcerative colitis — and found that roughly 3.5% produce self-attacking antibodies that block interleukin-10 (IL-10), a protein essential for dampening excessive inflammation in the gut. This autoimmune mechanism directly links a long-established genetic risk factor, the HLA-DRB1*01:03 variant, to severe disease outcomes, explaining why it has sat near the top of IBD genetic risk charts for three decades without a clear biological explanation. Based on UK prevalence data, the researchers estimate 15,000 to 20,000 patients in Britain alone may carry these harmful antibodies, making them candidates for a targeted treatment approach rather than the broad immunosuppressive regimens currently used. The discovery opens a pathway to a simple blood test to identify affected patients before they suffer the severest complications. Professor Simon Travis of Oxford called it "the most exciting discovery in a lifetime specialising in IBD." Approximately 500,000 people in the UK live with IBD, and millions more are affected around the world.